Research Submission: Tramadol-Acetaminophen for the Treatment of Acute Migraine Pain: Findings of a Randomized, Placebo-Controlled Trial

ObjectiveTo compare tramadol-acetaminophen (APAP) and placebo for the management of acute migraine pain. BackgroundTramadol-APAP tablets reduced moderate-to-moderately severe acute pain in controlled studies of other painful conditions. MethodsThis randomized, double-blind, placebo-controlled, parallel group study enrolled adults with migraine pain as per International Headache Society criteria. Subjects took tramadol-APAP (total dose, 75 mg-650 mg) or placebo for a typical migraine with moderate-to-severe pain. Severity of pain and migraine-related symptoms were recorded before study medication and at 0.5, 1, 2, 3, 4, 6, and 24 hours after study medication. ResultsEfficacy analyses included 305 subjects (154 tramadol-APAP and 151 placebo). Treatment response was higher for tramadol-APAP than a placebo at 2 hours after dosing (55.8% vs. 33.8%, P < .001) and at every other assessment from 30 minutes (12.3% vs. 6.6%) through 6 hours (64.9% vs. 37.7%) (all P less than or equal to .022). Subjects in the tramadol-APAP group were more likely than those in the placebo group to be pain-free at 2 hours (22.1% vs. 9.3%), 6 hours (42.9% vs. 25.2%), and 24 hours (52.7% vs. 37.9%) (all P less than or equal to .007). Two hours after dosing, moderate-to-severe symptoms that were less common for tramadol-APAP than placebo included photophobia (34.6% vs. 52.2%, P= .003) and phonophobia (34.3% vs. 44.9%, P= .008), but not migraine-related nausea (38.5% vs. 29.4%, P= .681). Treatment-related adverse events included nausea, dizziness, vomiting, and somnolence. ConclusionsTramadol-APAP reduces the severity of pain, photophobia, and phonophobia associated with migraine headache, but does not reduce migraine-associated nausea. Tramadol-APAP might be an appropriate option for the management of moderate-to-severe migraine headache.